Marketing Research is Power in Negotiations to Sell a Small Business by Latta, Michael
Georgia Southern University 
Digital Commons@Georgia Southern 
Association of Marketing Theory and Practice 
Proceedings 2013 
Association of Marketing Theory and Practice 
Proceedings 
2013 
Marketing Research is Power in Negotiations to Sell a Small 
Business 
Michael Latta 
Coastal Carolina University 
Follow this and additional works at: https://digitalcommons.georgiasouthern.edu/amtp-
proceedings_2013 
 Part of the Marketing Commons 
Recommended Citation 
Latta, Michael, "Marketing Research is Power in Negotiations to Sell a Small Business" (2013). 
Association of Marketing Theory and Practice Proceedings 2013. 40. 
https://digitalcommons.georgiasouthern.edu/amtp-proceedings_2013/40 
This conference proceeding is brought to you for free and open access by the Association of Marketing Theory and 
Practice Proceedings at Digital Commons@Georgia Southern. It has been accepted for inclusion in Association of 
Marketing Theory and Practice Proceedings 2013 by an authorized administrator of Digital Commons@Georgia 
Southern. For more information, please contact digitalcommons@georgiasouthern.edu. 
 Association of Marketing Theory and Practice Proceedings March 2013 1 
Copyright of the Author(s) and published under a Creative Commons License Agreement  
http://creativecommons.org/licenses/by-nc-nd/3.0/us/ 
MARKETING RESEARCH IS POWER IN NEGOTIATIONS TO 
SELL A SMALL BUSINESS 
 
Michael Latta 
Coastal Carolina University 
 
 
ABSTRACT 
 
Small firms are at a disadvantage in negotiations with larger firms and need to have something 
on their side of the table to give them power in the process.  Primary marketing research can 
provide proprietary information for the smaller firm that may be used to support a forecasting 
model to be used in evaluating offers during negotiations.  This paper describes such a 
negotiation supported by a proprietary forecasting simulator that created an advantage for the 
smaller firm over the larger firm.  As a result, the smaller firm had a go-it-alone baseline 
revenue forecast to determine the incremental value of a specific co-promotion or royalty 
arrangement, was able to adjust negotiation positions quickly ensuring that full value was 
obtained for the smaller firm in the sale. 
 
BACKGROUND 
 
Marketing research can play a key role in selling a firm, making an acquisition, or seeking a 
merger in the pharmaceutical industry.  This use of marketing research to support forecasting and 
negotiations is important in these situations because, in the current pharmaceutical environment, 
many large companies are experiencing patent loss on block-buster drugs and have few 
candidates to replace them.  Faced with a new product short-fall and declining revenues, many 
big pharmaceutical companies are turning to partnerships, joint ventures, mergers, and 
acquisitions involving smaller, more entrepreneurial firms to improve their product portfolios.  
Small companies can be at a disadvantage in negotiations with larger firms.  There is no shortage 
of advice about how to sell a business (Handelsman, 2012a; Handelsman, 2012b; Nigh & 
Boschetti, 2006; Rosenbloom, 2001; Warrillow, 2010).  It is demonstrated here that one way to 
level the playing field is to develop a forecasting simulator based on a market model informed by 
proprietary marketing research to use in real-time negotiations with a large company. 
 
WHEN A SMALL FIRM WANTS TO BE ACQUIRED 
 
When a small firm desires to be acquired by a larger firm, negotiations are many times even 
more difficult and protracted than usual.  A danger to the small firm is leaving money on the 
table and not getting the full value for the risk assumed in starting the company, developing a 
successful product, and building a business desired by the buyer firm  One way to avoid such 
situations is for the small seller firm to develop a detailed forecasting simulator that incorporates 
all the relevant assumptions and variables that can be easily modified on the spot to show the 
financial impact of various changes in the terms of the deal proposed by either the larger buyer 
firm or counterproposals from the seller firm. 
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Typically, the negotiations come in three phases.  These phases and the activities involved 
appear below. 
 
Phase Activities 
Preliminary Negotiations Secondary Data Analysis 
Public Information Analysis 
Internal Data Analysis 
Full Negotiations Proposals of Partnership, Joint 
Venture, Merger, or Acquisition 
Deal Structuring Converting a Proposal into a Deal 
 
BENEFITS OF A MARKETING RESEARCH BASED FORECASTING SIMULATOR 
 
Developing a forecasting simulator has several benefits to the seller firm when converting a 
proposal into a deal. Such a simulator allows: 
 
• A way to represent the structure, terms, and conditions of any buyer firm 
proposal 
• Representation of the seller firm’s own best proposal 
• On-the-spot changes in relevant variables to see what the bottom-line financial 
impact of a structured deal will be for both the seller and the buyer firms, as well 
as the financial impact in terms of net present value, internal rate of return, and 
revenues 
• A baseline revenue forecast if the deal is not formalized and the seller firm goes 
forward as a single entity 
• Leverage in the negotiation process 
 
AN EXAMPLE 
 
An illustration of the value of a marketing research supported forecasting simulator to a small 
firm comes from two companies who sell a highly specialized product to Nephrologists for use 
in patients with kidney disease.  In this example, both products are indicated for treatment of the 
side effects of dialysis.  The dialysis market has two relatively small patient populations, one in 
hemodialysis (HD) and one in peritoneal dialysis (PD).  The small firm has developed an oral 
product for use with a much larger market of pre-dialysis patients who have chronic kidney 
disease (CKD).  In the pharmaceutical industry, owning a New Drug Application (NDA) that 
will gain FDA approval is money in the bank.  The potential profits in the CKD market are huge 
relative to the HD and PD markets making the small firm an attractive acquisition for the large 
firm, especially since its new product pipeline was without near term candidates. 
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Negotiations began with two proposals, one from each side.  The structure of the proposals 
appears below.  In this example Product X is the seller’s product and Product Y is the buyer’s 
product.  The main difference in the proposals is that co-promotion is involved in the seller’s 
proposal and royalties are the main stay of the buyer’s proposal. 
 
In preparation for negotiations, the small firm built a market model and forecasting simulator in 
Excel following extensive primary marketing research which provided input for both products 
and various market segments.  The marketing research projects included individual depth 
interviews, focus groups, and quantitative surveys.  These projects were done domestically and 
internationally and were conducted over two years to provide input to the market models in 
preparation for negotiations.  The method of market modeling in pharmaceuticals has been well 
documented over the years (Latta, 1998a, Latta, 1998a, Latta, 2002). 
 
By way of summary, the market models incorporate 
 
• Marketing research data to reflect patient eligibility, product use, and days of 
therapy currently and the future growth rate of these variables 
• Historical data to set growth rates and patient population size 
• Internal data to reflect inventories, costs, resources, and prices 
• Any management assumptions about the future of the business including 
opportunities, threats, strengths, weaknesses, and organizational changes 
 
THE SELLER’S PROPOSAL 
 
The seller’s proposal structure appears below: 
 
Type of Agreement 
Co-promotion rights to CKD and oral Product X 0.5 mg capsules 
Cash Payments 
$10mm Upfront Payment at signing 
$25mm Approval Payment of CKD indication 
$10mm Commercial Success payments at attainment of each $100mm in 
sales 
Phase IV commitment for US is Buyer responsibility 
Buyer and Seller share profits 60/40 
Buyer books sales for CKD for 0.5 mcg capsules 
Marketing 
60/40 split in marketing costs 
Final marketing approval stays with NDA owner 
Other Provisions 
Sub License rights - Rest of the world (ROW) 
Product registration and other regulatory undertakings - Buyer would be 
responsible for all 
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Manufacturing - Buyer would be a secondary manufacturer for capsules 
and injection 
Next generation products - joint development of Product Z and Product W 
Exploration of other compounds already patented 
 
 
Conversion of the seller’s proposal into a five-year forecasting simulator supported by marketing 
research data following the market model approach appears below.
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TABLE 1 
SELLER’S CO-PROMOTION PROPOSAL REPRESENTED IN A MARKET MODEL FORECASTING SIMULATOR 
 
Year   1 2 3 4 5 
Revenue Stage III/IV CKD  $4,000,000 $23,000,000 $44,000,000 $69,000,000 $92,000,000 
WARF Royalty 3% $120,000 $690,000 $1,320,000 $2,070,000 $2,760,000 
Manufacturing Cost ($0.10 per 
cap) 0.10 $615,385 $3,402,367 $6,258,534 $9,437,038 $12,098,767 
Gross Margin  $3,264,615 $18,907,633 $36,421,466 $57,492,962 $77,141,233 
Gross Profit Split   
 60% $1,958,769 $11,344,580 $21,852,879 $34,495,777 $46,284,740 
 40% $1,305,846 $7,563,053 $14,568,586 $22,997,185 $30,856,493 
Selling expense  $8,000,000 $8,000,000 $8,800,000 $13,800,000 $18,400,000 
Number of seller reps @ 
$150,000/rep                       53 53 53 53 53
Marketing expense  $25,000,000 $25,000,000 $10,000,000 $6,900,000 $9,200,000  
Variable Contribution     $(29,735,385) $(14,092,367) $17,621,466 $36,792,962 $49,541,233  
Up Front payments         $15,000,000                       -                        -                        -                        -  
Royalties 0%                       -                        -                        -                        -                        -  
Net contribution  $(12,776,615) $(2,747,787) $39,474,345 $71,288,739 $95,825,973 
Net present Value to Buyer 12% $362,740,130.47  
IRR  160%  
  159%  
Total payments to Seller  $16,305,846 $7,563,053  $14,568,586 $22,997,185 $30,856,493 
Net present Value to Seller  $142,805,663.80  
0.5mcg Capsule Price (WAC)  $0.65 $0.68  $0.70 $0.73 $0.76 
Revenue - Go Alone Forecast   $                     -  $690,505   $3,449,040  $5,852,898  $7,621,300 
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THE BUYER’S PROPOSAL 
 
The buyer’s proposal structure appears below: 
 
Type of Agreement 
Royalty Payments 
Distribution stays with New Drug Application (NDA) owner 
Contracting stays with the NDA owner 
National Accounts are responsibility of NDA owner 
Other products could be added to contracts 
Seller promotes other products in CKD 
Primary detail – Product X (HD/PD) 
Secondary detail – Product Y (CKD) 
Buyer promotes Product X in CKD 
Primary detail – Product Y (CKD) 
Secondary detail – Product X (CKD) 
International Rights 
Buyer submits for approval in each country or region 
Buyer markets in each country 
Seller receives royalties based on sales of Product X in each country or region 
Booking of Sales 
Seller – Injection and 2.5 mcg capsules (HD/PD) 
Buyer – 0.5 mcg capsules (CKD) 
 
 
Conversion of the buyer’s proposal into a forecasting simulator following the market model 
approach appears below. 
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TABLE 2 
BUYER’S CO-PROMOTION PROPOSAL REPRESENTED IN A MARKET MODEL FORECASTING SIMULATOR 
 
Year   1 2 3 4 5 
Revenue Stage III/IV CKD  $4,000,000 $23,000,000 $44,000,000 $69,000,000 $92,000,000
WARF Royalty 3% $120,000 $690,000 $1,320,000 $2,070,000 $2,760,000
Manufacturing Cost ($0.10 per 
cap) 0.10 $615,385 $3,402,367 $6,258,534 $9,437,038 $12,098,767
Gross Margin  $3,264,615 $18,907,633 $36,421,466 $57,492,962 $77,141,233
Selling expense  $8,000,000 $8,000,000 $8,800,000 $13,800,000 $18,400,000
Number of seller reps @ 
$150,000/rep  53  
Marketing expense  $25,000,000 $25,000,000 $10,000,000 $6,900,000 $9,200,000
Variable Contribution  $(29,735,385) $(14,092,367) $17,621,466 $36,792,962 $49,541,233
Up Front payments  $15,000,000                         -                          -                          -                          -  
Royalties 25% $1,000,000 $5,750,000 $11,000,000 $17,250,000 $23,000,000
Net contribution  $(45,735,385) $(19,842,367) $6,621,466 $19,542,962 $26,541,233
Net present Value to Buyer 12% $45,903,234.05  
IRR  26%  
  24%  
Total payments to Seller  $16,000,000 $5,750,000 $11,000,000 $17,250,000 $23,000,000
Net present Value to Seller  $109,324,829.29  
0.5mcg Capsule Price (WAC)  $0.65 $0.68  $0.70 $0.73 $0.76  
4% price increase each year   
Revenue - Go Alone Forecast   $                       - $690,505  $3,449,040 $5,852,898 $7,621,300  
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IMPACT ON NEGOTIATIONS 
 
Because of the marketing research supported market model forecasting simulator, the smaller 
seller had the advantage in the negotiations.  At the first meeting, the marketing research 
professional brought the simulators to the negotiations.  The larger buyer company had no such 
tool available.  As the negotiations unfolded, the larger buyer tried to construct market models 
for use in the discussions.  However, their market models were incomplete since they lacked the 
two years of background marketing research the seller had available.  At the end of the 
negotiations, the smaller seller company realized their asking price and got terms and conditions 
of sale much to their advantage. 
 
CONCLUSIONS AND IMPLICATIONS 
 
Benefits of this approach to being acquired are valuable even if no final deal is struck.  The very 
process of self-examination of the business model, market position, financial matters, and 
operational issues adds significant value to the seller firm in the form of intellectual capital.  
Thorough understanding of assumptions, business operations, and the market environment makes 
a firm get stronger, more able to compete, and capable of developing a sustainable strategy.   
 
Benefits in the negotiation process include: 
 
• Having a go-it-alone baseline revenue forecast to determine the incremental value 
of a specific co-promotion or royalty arrangement. 
• Being able to adjust negotiation positions quickly and assessing the impact of the 
changes on both the buyer and seller firm. 
• Ensuring that full value is obtained for the seller firm. 
 
Smaller firms that are under consideration for acquisition by larger firms are urged to do 
comprehensive background proprietary marketing research, develop a market model, and create 
a forecasting simulator to use in negotiations. 
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